CGT Catapult teams with TrakCel for cell and gene therapy tracking – BioPharma-Reporter.com
BioPharma-Reporter.com |
CGT Catapult teams with TrakCel for cell and gene therapy tracking
BioPharma-Reporter.com CGT Catapult announced its partnership with TrakCel this week, explaining the UK firm’s supply chain management platform will be used to track cell and gene therapies made at the facility and stored at an adjacent warehouse being built by Fisher … |
BioPharma-Reporter.com |
Dude where’s my CAR–T? Personalised meds need personalised logistics, says TrakCel
BioPharma-Reporter.com The approval of Novartis’ Kymriah (tisagenlecleucel) this week heralds a new era of personalised medicine, and – if Gilead’s $11.9bn Kite investment pays off – soon two chimeric antigen receptor (CAR) T-cell therapies could be available in the US. |
BioPharma-Reporter.com |
Animal study shows benefit from gene therapy in late-stage eye disease
BioPharma-Reporter.com Up to now, animal studies had shown benefits from gene therapy only when it was used in the earliest stages of the disease. This research succeeded in improving retinal cells and preventing vision loss for 2 years in man’s best friend with a common and … |
BioPharma-Reporter.com |
Research shows neural stem cells strike a spinal cord in rat models
BioPharma-Reporter.com “We tested cells from a variety of sources, including ‘approved’ embryonic stem cell lines, as well as mouse and rat stem cells. We also reprogrammed cells from adult human skin to become neural cells, and drove these to spinal cord cells. This … |
BioPharma-Reporter.com |
Research shows neural stem cells strike a spinal cord in rat models
BioPharma-Reporter.com “We tested cells from a variety of sources, including ‘approved’ embryonic stem cell lines, as well as mouse and rat stem cells. We also reprogrammed cells from adult human skin to become neural cells, and drove these to spinal cord cells. This … |
BioPharma-Reporter.com |
Brammer leans on Pall for $50m cell & gene therapy plant expansions
BioPharma-Reporter.com This year, Brammer Bio has invested in its biomanufacturing capabilities, with a $40m expansion at its late-stage and commercial-ready cell and gene therapy facility in Cambridge, Massachusetts and a $10m expansion at a Phase I/II plant in Alachua, … |
BioPharma-Reporter.com |
Gilead aims to expand CAR–T manufacturing capabilities post-Kite acquisition
BioPharma-Reporter.com Until the US Food and Drug Administration (FDA) approved the first gene modified cell therapy product in the form of Novartis’ Kymriah (tisagenlecleucel), Gilead Science’s agreement to buy Kite Pharma was the biggest CAR–T cell-related story of the … “Chemotherapy will become just a bad memory”Globes Kite Pharma, Inc. (NASDAQ:KITE) Overbought but Is That a Sell Indicator?Highlight Press |
BioPharma-Reporter.com |
Oxford BioMedica could pocket $100m on Novartis CAR–T cell success
BioPharma-Reporter.com The US approval of the first autologous chimeric antigen receptor (CAR) T cell therapy Kymriah (tisagenlecleucel) has been heralded as a historic moment in cancer treatment, and at a price of $475,000 (€400,000) for a one-time infusion, is set to … |